Table 3.
Total cost and effectiveness of the detection and treatment of hypertension under the new and old guidelines.
| Old guidelines | New guidelines | Mean difference (95% CI) | Incremental cost-effectiveness ratio in £ sterling | |
|---|---|---|---|---|
| Base case (total costs in £ sterling) | 11.20 | 22.38 | 11.18 (10.69 to 11.67) | |
| Cardiovascular disease risk | 3.864 × 10−3 | 3.496 × 10−3 | 3.68 × 10−4 (3.24 to 4.12 × 10−4) | 30 384 |
| 6% discount rate on effects (total costs in £ sterling) | 11.20 | 22.38 | 11.18 (10.69 to 11.67) | |
| Cardiovascular disease risk | 2.932 × 10−3 | 2.653 × 10−3 | 2.79 × 10−4 (2.45 to 3.12 × 10−4) | 40 043 |
| Higher resource use under new guidelines (total costs in £ sterling) | 11.20 | 29.77 | 18.57 (14.20 to 24.70) | |
| Cardiovascular disease risk | 3.864 × 10−3 | 3.496 × 10−3 | 3.68 × 10−4 (3.24 to 4.12 × 10−4) | 50 454 |
| Lower effect of new guidelines (total costs in £ sterling) | 11.20 | 22.38 | 11.18 (10.69 to 11.67) | |
| Cardiovascular disease risk | 3.677 × 10−3 | 3.496 × 10−3 | 1.81 × 10−4 (1.60 to 2.08 × 10−4) | 61 775 |